Earendil Labs Files for Hong Kong IPO, Showcasing AI-Driven Pipeline Including TROP2/PD-L1, DLL3, and B7H3 ADCs

PharmaCircleMonitoring DisplayIndicates:Recently, Earendil Labs (and its affiliated company Helixon) has built a comprehensive pipeline of over 40 candidate molecules依托 AI 原生抗体研发平台, with 19 publicly disclosed and 15 entering the IND-enabling critical preclinical stage, primarily focusing on two major fields: autoimmune diseases and oncology; self-developed core products.HXN-1001For Long-Acting AntiTL1AMonoclonal antibody, Phase I clinical trial completed and Phase II clinical trial to be initiated soon, with indications covering ulcerative colitis, Crohn's disease, asthma, atopic dermatitis, etc.;

Authorization for SanofiSanofiTheHXN-1002（α4β7/TL1ADual Antibody) andHXN-1003（TL1A/IL-23Both antibodies) target inflammatory bowel disease and skin inflammation;

Internal self-developed pipeline also covers asthma, COPD, and other specific diseases.Atopic dermatitis, B-cell diseases and other autoimmune projects, in the field of oncologyDLL3、B7H3、TROP2/PL-L1 、EGFR/PD-L1、Claudin 18.2etc.Target development of bispecific antibodies, T-cell engagers (trispecific antibodies), and ADCs, covering solid tumors such as colorectal cancer and small cell lung cancer, with more than ten undisclosed preclinical projects planned for密集 IND submissions between 2026-2027, forming a multi-level R&D matrix that advances clinical-stage programs, rapidly incubates preclinical projects, and monetizes through external collaborations.

In addition, Sanofi is also its direct investor. The previous round of investors also includedDimension Capital、DST Global、Pfizer Biotech Development Fund, INCE Capital, Luminous Ventures, Miracle Capital, etc.

The founder is Peng Jian (Jian Peng, PhD), and the co-founder is Zhu Zhenping (Zhenping Zhu, MD, PhD).

PharmCube Data;

Moxie Pharma pharma.bcpmdata.com (formerly Pharma Data);

http://www.marketscreener.com；

https://www.businesswire.com；

www1.hkexnews.hk/；

; etc.